tert-butyl 4-{3-[(3R)-3-(ethoxycarbonyl)-1-piperidinyl]-3-oxopropyl}-1-piperidinecarboxylate | 169498-18-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: tert-butyl 4-{3-[(3R)-3-(ethoxycarbonyl)-1-piperidinyl]-3-oxopropyl}-1-piperidinecarboxylate
• 英文别名: tert-butyl (R)-4-(3-(3-(ethoxycarbonyl)piperidin-1-yl)-3-oxopropyl)piperidin-1-carboxylate；tert-butyl (R)-4-(3-(3-(ethoxycarbonyl)piperidin-1-yl)-3-oxopropyl)piperidine-1-carboxylate；(R)-ethyl 1-[3-(1-tert-butoxycarbonyl-4-piperidyl)propionyl]-3-piperidinecarboxylate；ethyl (3R)-1-[3-[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]propanoyl]piperidine-3-carboxylate
• CAS: 169498-18-4
• 化学式: C₂₁H₃₆N₂O₅
• 分子量: 396.527
• InChiKey: YUGURVRLIPCHBY-QGZVFWFLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  28
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  76.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-{3-[(3R)-3-(ethoxycarbonyl)-1-piperidinyl]-3-oxopropyl}-1-piperidinecarboxylate 在 lithium hydroxide 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 以 四氢呋喃 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 N-[(R)-1-{3-(1-tert-butoxycarbonyl-4-piperidyl)-propionyl}-3-piperidylcarbonyl]-β-alanine ethyl ester
  参考文献：
  名称：

  Design, synthesis, and structure–activity relationships of potent GPIIb/IIIa antagonists: discovery of FK419

  摘要：

  The discovery of the non-peptide antiplatelet injectable agent FK419 is reported. Based on the P-turn structure of RGD peptide sequences in the a chain of fibrinogen, which binds the glycoprotein IIb/IIIa (GPIIb/IIIa) on the surface of platelets to induce platelet aggregation, the prototype 2 was designed. After further substituent effects were investigated at the a-position of the carboxylic acid in 2, we enhanced platelet aggregation inhibition, and discovered the useful feature of reduced prolongation of bleeding time. Finally, the potent platelet aggregation inhibitor FK419 (3) could be discovered. FK419 shows a safe feature of reduced prolongation of bleeding time, as well as potent inhibition of platelet aggregation. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.03.056
• 作为产物：
  描述：

  ethyl (E)-3-(4-pyridyl)propenoate 在 platinum(IV) oxide 盐酸 、 sodium hydroxide 、 氢气 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 三乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 生成 tert-butyl 4-{3-[(3R)-3-(ethoxycarbonyl)-1-piperidinyl]-3-oxopropyl}-1-piperidinecarboxylate
  参考文献：
  名称：

  Design, synthesis, and structure–activity relationships of potent GPIIb/IIIa antagonists: discovery of FK419

  摘要：

  The discovery of the non-peptide antiplatelet injectable agent FK419 is reported. Based on the P-turn structure of RGD peptide sequences in the a chain of fibrinogen, which binds the glycoprotein IIb/IIIa (GPIIb/IIIa) on the surface of platelets to induce platelet aggregation, the prototype 2 was designed. After further substituent effects were investigated at the a-position of the carboxylic acid in 2, we enhanced platelet aggregation inhibition, and discovered the useful feature of reduced prolongation of bleeding time. Finally, the potent platelet aggregation inhibitor FK419 (3) could be discovered. FK419 shows a safe feature of reduced prolongation of bleeding time, as well as potent inhibition of platelet aggregation. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.03.056

文献信息

• Synthesis and evaluation of new polyenic compounds as potential PPARs modulators
  作者：Dominique Amans、Véronique Bellosta、Catherine Dacquet、Alain Ktorza、Nathalie Hennuyer、Bart Staels、Daniel-Henri Caignard、Janine Cossy

  DOI：10.1039/c2ob25593f

  日期：——

  In order to identify new leads for the treatment of type 2 diabetes, polyenic molecules A and B derived from nipecotic acid and dienol derivatives C have been prepared and their effect on PPARs transcriptional activity evaluated and compared to that of rosiglitazone, WY14,643 and GW501516. Among the synthesized compounds, dienol 39 is the most active, increasing WY14,643 PPARα response and demonstrating partial agonist properties on rosiglitazone PPARγ.

  为了找到治疗 2 型糖尿病的新线索，我们制备了由尼泊金酸衍生的多烯分子 A 和 B 以及二烯醇衍生物 C，评估了它们对 PPARs 转录活性的影响，并与罗格列酮、WY14,643 和 GW501516 进行了比较。在合成的化合物中，二烯醇 39 的活性最高，它能提高 WY14,643 PPARα 的反应，并显示出对罗格列酮 PPARγ 的部分激动特性。
• Beta-alanine derivative and a process for the preparation thereof
  申请人：Fujisawa Pharmaceutical Co., Ltd

  公开号：US06380215B1

  公开（公告）日：2002-04-30

  This invention relates to &bgr;-alanine derivatives represented by the following formula: wherein each symbol is as defined in the specification and pharmaceutically acceptable salt thereof which is glycoprotein IIb/IIIa antagonist, inhibitor of blood platelets aggregation and inhibitor of the binding of fibrinogen to blood platelets, to processes for the preparation thereof, to a pharmaceutical composition comprising the same and to a method for the prevention and/or treatment diseases indicated in the specification to a human being or an animal.

  本发明涉及以下式子所表示的&bgr;-丙氨酸衍生物：其中每个符号如规范中所定义的药物学上可接受的盐，其是糖蛋白IIb/IIIa拮抗剂，血小板聚集抑制剂和纤维蛋白原与血小板结合抑制剂，以及其制备方法，包括该物的制药组合物，以及用于预防和/或治疗规范中指示的人类或动物疾病的方法。
• KR102207372
  申请人：——

  公开号：——

  公开（公告）日：——
• US2023/142546
  申请人：——

  公开号：——

  公开（公告）日：——